Xience (everolimus-eluting stent) / Abbott - LARVOL DELTA

Long-term safety, effectiveness, and cost of rapamycin- vs. everolimus-eluting stents in acute coronary syndrome: a real-world cohort study. (PubMed, Int J Clin Pharm) - "Rapamycin-eluting stents demonstrated long-term safety and effectiveness comparable to everolimus-eluting stents in ACS patients post-PCI while offering a significant cost advantage. These findings suggest that rapamycin-eluting stents are potentially more cost-effective. For healthcare systems seeking to enhance value-based procurement, these results justify the preferential selection and wider adoption of rapamycin-eluting stents in clinical practice. However, confirmation through large-scale, multicenter, prospective studies is warranted."

Journal • Real-world evidence • Acute Coronary Syndrome • Cardiovascular • Diabetes • Dyslipidemia • Hypertension • Metabolic Disorders

BIOMAG-III: Safety and Clinical Performance of the Freesolve Resorbable Magnesium Scaffold (RMS) System in Subjects With Coronary Artery Lesions (clinicaltrials.gov) - P=N/A | N=1859 | Not yet recruiting | Sponsor: Teleflex

New trial • Acute Coronary Syndrome • Atherosclerosis • Cardiovascular • Coronary Artery Disease • Heart Failure • Myocardial Ischemia • Pain

Impact of diabetes mellitus on one-year outcomes of bioresorbable versus durable polymer drug-eluting stents in patients undergoing percutaneous coronary intervention following rotational atherectomy: Results from a large prospective registry. (PubMed, Am Heart J Plus) - "Patients with diabetes mellitus (DM) have worse outcomes after percutaneous coronary intervention (PCI), even with everolimus-eluting stents (EES)...In both BP-EES and DP-EES groups, there was no significant difference in adjusted risk of MACE (BP-EES: 7.3 % vs. 7.1 %, HR 0.78, 95 % CI 0.35-1.78, P = 0.562 & DP-EES: 7.5 % vs. 3.7 %, HR 1.49, 95 % CI 0.89-2.50, P = 0.130) between diabetics and non-diabetics. Despite differences in baseline characteristics, DM was not associated with worse MACE at one year in patients with complex coronary artery disease undergoing RA and PCI with contemporary BP-EES or DP-EES."

Journal • Cardiovascular • Coronary Artery Disease • Diabetes • Metabolic Disorders • Myocardial Infarction

The TRANSEVER registry - A prospective, open-label, multicentre, post market surveillance study of ISAR SUMMIT polymer-free Everolimus eluting stent in a real-world Indian population of patients with coronary artery disease: One-year outcomes of the first 500 enrolled patients. (PubMed, Int J Cardiol) - "The one-year outcomes in this cohort of patients with a low rate of TLF and stent thrombosis support the favorable safety and efficacy profile of the polymer-free everolimus-eluting ISAR SUMMIT in a real-world Indian population with CAD."

Journal • P4 data • Real-world evidence • Acute Coronary Syndrome • Cardiovascular • Coronary Artery Disease • Diabetes • Dyslipidemia • Hematological Disorders • Hypertension • Metabolic Disorders • Myocardial Infarction • Pulmonary Arterial Hypertension • Thrombosis

A randomized prospective study investigating the relationship between post-PCI wall shear stress and 12-month neointimal healing: The SHEAR-STENT study. (PubMed, Cardiovasc Revasc Med) - P=N/A | "The SHEAR-STENT study demonstrated no significant differences in WSS or NIT at 12 months between R-ZES and X-EES. A wide range of patient level correlation coefficients between WSS and NIT were observed, with some patients showing increased NIT was associated with low WSS and others associated with high WSS."

Journal • Diabetes • Dyslipidemia • Metabolic Disorders • Nephrology • Renal Disease

BIOMAG-II: Safety and Clinical Performance of the Freesolve Resorbable Magnesium Scaffold System (clinicaltrials.gov) - P=N/A | N=1859 | Recruiting | Sponsor: Biotronik AG | Not yet recruiting ➔ Recruiting

Enrollment open • Acute Coronary Syndrome • Atherosclerosis • Cardiovascular • Coronary Artery Disease • Heart Failure • Myocardial Ischemia

Early Oral Anticoagulation Monotherapy After PCI: Insights from the POEM Trial. (PubMed, Am Heart J) - P4 | "In HBR patients after PCI, transition to OAC monotherapy at 1 month was associated with low ischemic and bleeding risks, comparable to single antiplatelet therapy. These findings support early OAC monotherapy as a feasible strategy warranting randomized investigation."

Journal • Monotherapy • Cardiovascular • Hematological Disorders • Myocardial Infarction • Thrombosis

The efficacy of biodegradable polymer everolimus-eluting stents in patients with cardiac allograft vasculopathy. (PubMed, JHLT Open) - "PCI with BP-DES was associated with a lower TVNLR than PCI with DP-DES. Both DES resulted in similar clinical outcomes; however, a long-term investigation is warranted."

Journal • Cardiovascular • Inflammation • Transplantation

A Study Evaluating the Vascular Healing and Neointimal Transformation at 1 Month After Implantation of BioFreedom™ Drug-coated Stents and the Xience Drug-eluting Stent System in Patients With Acute Coronary Syndrome and High Bleeding Risk Using Optical Coherence Tomography (clinicaltrials.gov) - P=N/A | N=60 | Not yet recruiting | Sponsor: China National Center for Cardiovascular Diseases

New trial • Acute Coronary Syndrome • Cardiovascular • Coronary Artery Disease • Heart Failure

Ticagrelor versus Prasugrel in Patients with Diabetes Mellitus and Multivessel Coronary Artery Disease Undergoing Percutaneous Coronary Intervention: A Randomized Comparison from the TUXEDO-2 Trial (AHA 2025) - "Patients with diabetes mellitus and angiographically confirmed MVD were randomized 1:1 to either SupraflexCruz SES or Xience EES and to receive either ticagrelor or prasugrel (factorial design), each in combination with aspirin, as part of DAPT. TUXEDO-2 will help address the question of whether there are differences in clinical outcomes between ticagrelor or prasugrel in patients with diabetes and MVD undergoing PCI using contemporary drug eluting stents."

Clinical • Late-breaking abstract • Acute Coronary Syndrome • Cardiovascular • Coronary Artery Disease • Diabetes • Metabolic Disorders

Complex all-comers and patients with diabetes and prediabetes treated with Xience Sierra everolimus-eluting stents: COASTLINE high-risk. (PubMed, Eur Heart J Open) - P=N/A | "After enrolment, HR patients were identified according to prespecified criteria, and per protocol compared with HR patients treated in two randomized all-comer trials with Resolute-type zotarolimus-eluting stents (ZES). The significant difference in TVMI was driven by periprocedural events, as a landmark analysis at 7 days found no between-stent differences. https://clinicaltrials.gov/study/NCT04475380."

Journal • Cardiovascular • Coronary Artery Disease • Diabetes • Metabolic Disorders • Myocardial Infarction

Are Ultrathin Stents Optimal for Bifurcation Lesions? Insights From Computational Modeling of Provisional and DK-Crush Techniques. (PubMed, Catheter Cardiovasc Interv) - "Stent design influenced outcomes more strongly in PSB, where anatomical interaction and platform-specific behavior impacted both structural and hemodynamic results. In DKC, procedural complexity minimized those differences, making the stenting technique the primary performance driver. Nonetheless, Orsiro consistently preserved more favorable flow conditions. These findings highlight the need to match device selection with lesion characteristics in PSB, while in DKC, optimizing procedural steps may have a greater impact than the choice of stent platform."

Journal

Coronary Stents: All Those Trials. (PubMed, Int J Angiol) - "The promise of bioresorbable stents was dimmed by the findings of the ABSORB II trial (Bioresorbable Everolimus-Eluting Scaffold Versus a Metallic Everolimus-Eluting Stent). The findings of the SYNTAX (Synergy between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery) trial suggests that the majority of patients with left main stem and three vessel coronary artery disease are better served by coronary artery bypass surgery rather than angioplasty with drug-eluting stents."

Journal • Review • Acute Coronary Syndrome • Cardiovascular • Coronary Artery Disease • Hematological Disorders • Thrombosis

Short Dual Antithrombotic Therapy after PCI in Patients with Atrial Fibrillation: OPTIMA-AF trial (AHA 2025) - "PCI was performed with the XIENCE™ everolimus-eluting stent...CONCLUSIONSThe OPTIMA-AF trial, involving patients with AF and stable coronary artery disease undergoing PCI, will provide data on the efficacy and safety of the 1-month dual antithrombotic therapy followed by DOAC monotherapy as compared to the 12-month dual antithrombotic therapy. (jRCTs051190053)"

Clinical • Late-breaking abstract • Atrial Fibrillation • Cardiovascular • Coronary Artery Disease • Ischemic stroke

Ultra-low thickness bio-degradable polymer Vs durable polymer Everolimus eluting stents - A 24 months clinical follow-up study. (PubMed, Indian Heart J) - "These findings suggest that biodegradable and durable polymer platforms offer similar long-term performance. The Eternia stents demonstrated equivalent safety and efficacy to Xience stents at 24 months."

Journal • Cardiovascular • Hematological Disorders • Thrombosis

Late Stent Thrombosis After Biodegradable Polymer Everolimus-Eluting Stent in a Cancer Patient Receiving Bevacizumab. (PubMed, JACC Case Rep) - "This case illustrates late stent thrombosis despite complete re-endothelialization on the biodegradable polymer EES, suggesting that both the patient's cancer-related prothrombotic state and his anti-VEGF therapy may have overcome the theoretical safety advantage of the stent."

Journal • Cardiovascular • Hematological Disorders • Hepatocellular Cancer • Myocardial Infarction • Oncology • Solid Tumor • Thrombosis

TRANSFORM II: Sirolimus-coated Balloon Versus Drug-eluting Stent in Native Coronary Vessels (clinicaltrials.gov) - P=N/A | N=1820 | Active, not recruiting | Sponsor: Fondazione Ricerca e Innovazione Cardiovascolare ETS | Recruiting ➔ Active, not recruiting | Trial primary completion date: Nov 2024 ➔ Nov 2025

Enrollment closed • Trial primary completion date • Cardiovascular • Coronary Artery Disease

Effectiveness and Safety of CENTUM™, an Everolimus-Eluting Stent, in Patients With Coronary Artery Disease: A Prospective Multi-Center Observational Study. (PubMed, Korean Circ J) - "CENTUM was effective and safe at 12 months in all patients who underwent percutaneous coronary intervention. Our findings support the broader application of CENTUM in patients with coronary artery disease."

Journal • Observational data • Acute Coronary Syndrome • Cardiovascular • Coronary Artery Disease • Hematological Disorders • Myocardial Infarction • Thrombosis

PROMUS PREMIER™ China Post-Approval Study (clinicaltrials.gov) - P=N/A | N=2059 | Completed | Sponsor: Boston Scientific Corporation | Trial completion date: Mar 2025 ➔ Aug 2025

Trial completion date • Cardiovascular • Coronary Artery Disease

DestinACSion: Comparison of a Contemporary Sirolimus-eluting Stent (ihtDEStiny®) With Another Everolimus-eluting Stent (Xience™), Both With Permanent Polymers, in Patients With Acute Coronary Syndrome and de Novo Coronary Artery Lesions (clinicaltrials.gov) - P=N/A | N=2100 | Not yet recruiting | Sponsor: Fundación EPIC

New trial • Acute Coronary Syndrome • Cardiovascular • Coronary Artery Disease

Side Branch Occlusion After Intravascular Lithotripsy: A Case Report. (PubMed, Cureus) - "After pre-dilation with a 2.5/13 mm scoring balloon distally and a 3.0/15 mm non-compliant balloon proximally, a 2.5/38 mm everolimus-eluting stent was implanted, and the proximal segment was post-dilated with a 3.0/15 mm non-compliant balloon...No protective wiring had been performed initially as the affected SB was <1.5 mm, but the subsequent ischemic event indicated it should be considered a significant branch. Angiography before and after IVL showed no change suggestive of SB risk, whereas OCT performed immediately after IVL revealed new protrusion of fractured calcifications into the D1 and D3 ostia, which was considered the cause of the subsequent side branch occlusion. IVL-related SB occlusion is an extremely rare complication in the literature, but meticulous pre-procedural OCT assessment and consideration of protective wiring in high-risk bifurcation lesions may help predict and prevent this event."

Journal • Cardiovascular • Musculoskeletal Diseases • Myocardial Infarction • Pain

A pharmacokinetic comparison between three drug delivery devices in porcine coronary arteries. (PubMed, Cardiovasc Revasc Med) - "SEL-SEB shows sustained arterial drug retention, more closely resembling the gold-standard EES. This data suggests that SEL-SEB should produce durable outcomes without the need for a permanent implant."

Journal • PK/PD data • Preclinical • Atherosclerosis

5-Year Outcomes With a Novel Coronary Sirolimus-Eluting Bioresorbable Scaffold: The NeoVas Randomized Trial. (PubMed, JACC Cardiovasc Interv) - P=N/A | "At 5-year follow-up, target lesion failure and stent thrombosis rates were comparable after NeoVas BRS and CoCr EES implantation in noncomplex lesions. However, comparability or the potential signs of harm of NeoVas BRS should be investigated in appropriately sized randomized trials in the future. (NeoVas Bioresorbable Coronary Scaffold Randomized Controlled Trial; NCT02305485)."

Clinical • Journal • Cardiovascular • Coronary Artery Disease • Hematological Disorders • Thrombosis

CONNECT: A Randomized Comparison of Long-Term Healing Between Biodegradable- Versus Durable-Polymer Everolimus Eluting Stents in STEMI (clinicaltrials.gov) - P=N/A | N=240 | Completed | Sponsor: Tokorozawa Heart Center | Active, not recruiting ➔ Completed

Trial completion • Cardiovascular • Myocardial Infarction

Benefit of coronary stenting using available intracoronary tools in high-risk patients. The OPTI-XIENCE study. (PubMed, Int J Cardiol) - "The use of any ICT for stent optimization in high-risk PCI significantly improves clinical outcomes compared to angiographic guidance alone. These findings support an individualized use of ICT to optimize complex PCI outcomes."

Journal • Cardiovascular • Hematological Disorders • Myocardial Infarction • Thrombosis